Circulating endothelial cells in sickle cell disease

Circulating endothelial cells in sickle cell disease - CEC in SCD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30432

Enrollment

Registered

2007-03-15

Start date

2007-06-28

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle cell Sickle cell anemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. High performance liquid chromatography confirmed diagnosis of HbSS or HbSb0-thalassemia genotype. 2. Written informed consent by the patient. 3. For healthy controls: HbAA genotype, race sex and age matched blood donors, written informed consent.

Exclusion criteria

Exclusion criteria: 1. Blood transfusion in the preceding three months. 2. Painful crisis/acute chest syndrome/stroke or other acute complications in the preceding 2 weeks. 3. Pregnancy, active cancer, active infection, connective tissue diseases. 4. For healthy controls: any current disease

Design outcomes

Primary

Measure	Time frame
1. Comparison of the number of CEC in sickle cell patients to the number in healthy controls.	—

Secondary

Measure	Time frame
2. To study the relationship of CEC to the history of clinical vaso-occlusion (e.g., the frequency of painful crises). 3. To analyze the relationship of CEC to established organ damage and dysfunction. 4. To determine the relationship of CEC to laboratory risk factors for poor outcome (e.g., the degree of anemia and the percentage of fetal haemoglobin). 5. To analyze the relationship of CEC to other biomarkers of disease activity (e.g. endothelial activation and fucntion, the hypercoagulable state and angiogenesis.	—

Measure

Time frame

2. To study the relationship of CEC to the history of clinical vaso-occlusion (e.g., the frequency of painful crises). 3. To analyze the relationship of CEC to established organ damage and dysfunction. 4. To determine the relationship of CEC to laboratory risk factors for poor outcome (e.g., the degree of anemia and the percentage of fetal haemoglobin). 5. To analyze the relationship of CEC to other biomarkers of disease activity (e.g. endothelial activation and fucntion, the hypercoagulable state and angiogenesis.

—

Countries

Netherlands

Outcome results